Qualigen Therapeutics, Inc. — Director's Dealing 2021

May 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Qualigen Therapeutics, Inc. (QLGN)
CIK: 0001460702
Period of Report: 2021-05-17

Reporting Person: ARSHAD TARIQ (SVP/Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-17	Stock Option (Right to Buy)	$1.80	A	100000	Acquired	2031-05-17	Common Stock (100000)	Direct

Footnotes

F1: Shares underlying the stock option vest over three years in three equal annual installments from the date of grant.